Discipline of Laboratory Medicine, School of Medical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Discipline of Pharmacy, School of Medical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Drug Discov Today. 2014 Sep;19(9):1387-93. doi: 10.1016/j.drudis.2014.03.026. Epub 2014 Apr 6.
Recently, aberrant epigenetic modifications have been identified in the pathogenesis of the posterior eye diseases, age-related macular degeneration (AMD) and diabetic retinopathy (DR). This has led to the development of alternative therapies that can alter aberrant chromatin-remodelling processes involved in AMD and DR. These novel therapeutic agents could help to ameliorate the challenges associated with current treatments that are limited by variable patient response and disease heterogeneity. However, research on the use of epigenetic-based therapies in these diseases is relatively young and, therefore, preclinical studies that evaluate their mechanism of action, specificity and adverse effects are warranted.
最近，在后眼部疾病、年龄相关性黄斑变性 (AMD) 和糖尿病性视网膜病变 (DR) 的发病机制中发现了异常的表观遗传修饰。这导致了能够改变与 AMD 和 DR 相关的异常染色质重塑过程的替代疗法的发展。这些新型治疗药物可以帮助改善与当前治疗方法相关的挑战，这些治疗方法受到患者反应和疾病异质性的限制。然而，在这些疾病中使用基于表观遗传的治疗方法的研究相对较新，因此，需要进行评估其作用机制、特异性和不良反应的临床前研究。
